Open AccessUstekinumab in Crohn's disease: real-world outcomes and predictors of response.
Author(s) -
Laura Lorenzo González,
Teresa Valdés Delgado,
Juan María Vázquez Morón,
Luisa Castro Laria,
Eduardo Leo Carnerero,
Manuel Jesús Soriano Pérez,
Damián Sánchez Capilla,
Héctor Pallarés Manrique,
Antonia Sáez Díaz,
Federico Argüelles Arias,
Grupo de Enfermedad Inflamatoria de Andalucía
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.7352/2020
Subject(s) - ustekinumab , medicine , crohn's disease , observational study , gastroenterology , ulcerative colitis , disease , vedolizumab , adalimumab
ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the treatment of Crohn's disease (CD) and, more recently, also ulcerative colitis (UC). The aim of this study was to evaluate the effectiveness and safety of ustekinumab, as well as to identify possible predictive factors of response in a real-life setting.